Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gary Patou Sells 4,891 Shares

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gary Patou sold 4,891 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the transaction, the director now directly owns 23,573 shares in the company, valued at approximately $968,378.84. This represents a 17.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Xenon Pharmaceuticals Trading Up 3.4 %

Shares of XENE stock opened at $41.15 on Friday. Xenon Pharmaceuticals Inc. has a 1-year low of $28.20 and a 1-year high of $50.99. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of -14.59 and a beta of 1.25. The stock’s fifty day simple moving average is $41.23 and its 200-day simple moving average is $40.23.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same period in the previous year, the company posted ($0.73) earnings per share. On average, sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Institutional Trading of Xenon Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Blue Trust Inc. boosted its stake in shares of Xenon Pharmaceuticals by 174.7% during the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 641 shares in the last quarter. nVerses Capital LLC acquired a new position in Xenon Pharmaceuticals in the 3rd quarter valued at approximately $102,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Xenon Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 487 shares in the last quarter. Quarry LP raised its holdings in Xenon Pharmaceuticals by 207.7% in the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock valued at $156,000 after acquiring an additional 2,700 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of Xenon Pharmaceuticals by 12.0% in the 1st quarter. ProShare Advisors LLC now owns 5,286 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 565 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. William Blair upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright reiterated a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Wedbush lowered their price target on Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating on the stock in a research report on Friday, August 9th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus target price of $57.45.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.